Bh. Kushner et al., HIGH-RISK OF LEUKEMIA AFTER SHORT-TERM DOSE-INTENSIVE CHEMOTHERAPY INYOUNG-PATIENTS WITH SOLID TUMORS, Journal of clinical oncology, 16(9), 1998, pp. 3016-3020
Purpose: To help fill the gap in knowledge about the risk of leukemia
from repetitive high-dose use of alkylating agents and topoisomerase-I
I inhibitors in young patients with solid tumors. Methods: Poor risk s
olid tumors were treated with four courses of cyclophosphamide (4,200
mg/m(2))/doxorubicin (75 mg/m(2)), and three courses of ifosfamide (9,
000 mg/m(2))/etoposide (500 mg/m(2)). The cumulative incidence of trea
tment-related myelodysplasia/leukemia (t-AML) was calculated using the
method of competing risks. The expected number of leukemic events was
calculated by applying national incidence rates to person-years class
ified by age and sex. Results: Among 86 patients (median age, 17 years
) monitored for 6 to 88 months (median, 24), five cases of t-AML were
detected at 10 to 37 months (median, 17). The expected number of leuke
mic events in this cohort was .001. Clinical and cytogenetic findings
implicated prior alkylator therapy in three cases and prior treatment
with topoisomerase-II inhibitors in two. At 40 months, the cumulative
incidence of t-AML was 8% (SE 7%). Conclusion: Repetitive high dose us
e of alkylating agents given with topoisomerase-II inhibitors is stron
gly leukemogenic, even with modest cumulative doses of each drug. This
finding is notable for the following reasons: (1) it undermines predi
ctions that limited use of high-dose chemotherapy might be minimally l
eukemogenic, and (2) it contrasts strikingly with the previously repor
ted low risk of t-AML following treatment of pediatric solid tumors wi
th chemotherapy lacking the alkylator dose-intensity and prominence of
etoposide that are hallmarks of current regimens, J Clin Oncol 16:301
6-3020. (C) 1998 by American Society of Clinical Oncology.